Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Smith & Nephew plc (SNN) vs Under Armour Inc Class A (UA) Price & Performance

Smith & Nephew plcTrade
Under Armour Inc Class ATrade

Price performance (Past 24H)

Key statistics

Smith & Nephew plc vs Under Armour Inc Class A — how do they compare? Smith & Nephew plc trades at $30.05 (market cap $12.54B), while Under Armour Inc Class A trades at $5.09 (market cap $2.26B). The key difference: Smith & Nephew plc is far larger — about 5.5× Under Armour Inc Class A's market cap, and Smith & Nephew plc pays a 2.65% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.

SNNUA
Market Cap
$12.54B$2.26B
Sector
HealthConsumer Cyclical
52-Week High
$38.70$7.88
52-Week Low
$28.73$3.96
Enterprise Value
$15.57B$3.24B
Dividend Yield
2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Smith & Nephew plc

SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.

The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.

Under Armour Inc Class A

Under Armour (UA) is trading at $5.12, down 9.78% with bearish technical signals despite some oversold RSI readings. The company faces significant fundamental challenges with negative net income margins (-9.99%) and declining revenue trends from $5.16B in 2025 to $4.9B in 2026. Recent Q1 2027 results showed a revenue decline of 3% to $1.1B, prompting management to lower full-year revenue guidance amid softer consumer demand in key markets.

The outlook remains challenging with persistent profitability issues and negative cash flow trends. While analyst sentiment shows mixed ratings (38.81% Buy, 49.25% Hold), the stock trades at attractive valuation multiples (P/S 0.45) but faces execution risks in its turnaround strategy. Key risks include competitive pressures, inventory management challenges, and macroeconomic headwinds affecting consumer spending.

Returns comparison

Trailing returns across standard periods

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN

About Under Armour Inc Class A

Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.

Read more on UA